RedHill buys commercialization rights for Ferring GI drugs
RedHill says its acquisition from Ferring of commercialization rights to Rebyota® and Clenpiq®, together with the previously announced Talicia® divestiture, completes a strategic divestiture plan.
Story updates
11:00:57 AM UTC
SquawkNews
RDHL - RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
11:01:39 AM UTC
SquawkNews
RDHL RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
11:02:16 AM UTC
SquawkNews
RDHL - RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
Together with the previously announced Talicia® strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately $37.5 million in 2025 net sales, completes a major s…